Bioprojet SCR

Bioprojet is a long-established, private French biopharmaceutical firm with a core competency in small molecule drug discovery and development, particularly in neuroscience. The company has successfully transitioned discoveries into a commercial portfolio, including the flagship product Wakix® (pitolisant) for narcolepsy, and maintains an active R&D pipeline. With a human-scale, agile research model and international commercial partnerships, Bioprojet leverages its integrated research center near Rennes to pursue novel therapeutic targets, aiming to address significant unmet medical needs in neurology and psychiatry.

Integrated small molecule drug discovery platform focused on neuropharmacology, with specialized units in biochemistry, therapeutic chemistry, pharmacology, and pharmacokinetics. Built on foundational work in histamine receptor research (notably H3).

In narcolepsy, Wakix® competes with traditional stimulants (e.g., modafinil) and sodium oxybate, with its novel mechanism being a key differentiator. In its other therapeutic areas, it faces competition from large pharmaceutical companies and generic manufacturers, competing on efficacy, safety, and niche positioning.